ReviewCurrent treatment options in oncology2020
The Benefits of Olanzapine in Palliating Symptoms.
Review in Current treatment options in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Olanzapine as a prophylactic antiemetic for preventing postoperative nausea and vomiting after general anesthesia: A systematic review and meta-analysis.Clinics (Sao Paulo, Brazil) · 2024Pooled it
- Clinical insights into the management of sleep disturbances within cancer care: a qualitative analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Efficacy of short-term, low-dose oral olanzapine at reducing perioperative anxiety, pain, and enhancing recovery in patients undergoing primary total joint arthroplasty.International journal of surgery (London, England) · 2026Article
- A case report: Treating insomnia with olanzapine in cancer patients.Palliative & supportive care · 2025Article
- Appetite Loss in Patients with Advanced Cancer Treated at an Acute Palliative Care Unit.Current oncology (Toronto, Ont.) · 2024Article
- A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome.Pharmacy (Basel, Switzerland) · 2024Review
- Olanzapine for the prevention of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a randomized controlled trial.Therapeutic advances in drug safety · 2024Article
- Consensus on the pharmacological treatment of acute stress disorder in Chinese pilots: a Delphi study.BMC psychiatry · 2023Article
- Eco-friendly synthesis of new olanzapine derivatives and evaluation of their anticancer potential.RSC advances · 2023Article
- The Role of Dopamine in Repurposing Drugs for Oncology.Biomedicines · 2023Review
- Insomnia among Cancer Patients in the Real World: Optimising Treatments and Tailored Therapies.International journal of environmental research and public health · 2023Review
- Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug.Current oncology (Toronto, Ont.) · 2022Review
- Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions.Current research in pharmacology and drug discovery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
opinion statementOlanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. In addition, a recent randomized trial has demonstrated its benefits in treating nausea and vomiting associated with advanced cancer. The added benefit to olanzapine is that it also stimulates appetite. As a result, since it treats multiple symptoms associated with advanced cancer, it is likely to become the antiemetic of choice in palliative care at least in the USA. The added benefit of treating insomnia and the avoidance of benzodiazepines should place olanzapine in at the top of the list of drugs to use for patients who do complain of insomnia. There is no good evidence that it potentiates the respiratory depression of opioids unlike benzodiazepines. The evidence is weak that olanzapine in as an adjuvant analgesic. Hopefully, future trials will explore this in greater depth. The benefits of adding olanzapine to potent opioids are that it may reduce craving, drug cues, and opioid misuse. Other symptoms like anxiety and depression may be addressed by the addition of olanzapine to standard antidepressants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.